AKYA logo

Akoya Biosciences (AKYA)

Profile

Full Name

Akoya Biosciences, Inc.

Ticker Symbol

AKYA

Exchange

NASDAQ

Country

United States

IPO

April 16, 2021

Indexes

Not included

Employees

205

Key Details

Price

$1.15

Market Cap

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$81.67M(-15.48% YoY)

Annual EPS

-$1.12(+21.68% YoY)

PE Ratio

-

Next earnings date

May 13, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Mar 25, 25 Stephens & Co.
Equal-Weight
Mar 18, 25 Stephens & Co.
Overweight
Nov 19, 24 Piper Sandler
Overweight
Nov 15, 24 Craig-Hallum
Hold
Nov 15, 24 Canaccord Genuity
Buy
Aug 13, 24 Piper Sandler
Overweight
Aug 6, 24 Morgan Stanley
Equal-Weight
Aug 6, 24 JP Morgan
Neutral
Aug 6, 24 Craig-Hallum
Buy
Aug 6, 24 BTIG
Neutral

Institutional Ownership

  • What is the ticker symbol for Akoya Biosciences?
  • Does Akoya Biosciences pay dividends?
  • What sector is Akoya Biosciences in?
  • What industry is Akoya Biosciences in?
  • What country is Akoya Biosciences based in?
  • When did Akoya Biosciences go public?
  • Is Akoya Biosciences in the S&P 500?
  • Is Akoya Biosciences in the NASDAQ 100?
  • Is Akoya Biosciences in the Dow Jones?
  • When was Akoya Biosciences's last earnings report?
  • When does Akoya Biosciences report earnings?
  • Should I buy Akoya Biosciences stock now?

What is the ticker symbol for Akoya Biosciences?

The ticker symbol for Akoya Biosciences is NASDAQ:AKYA

Does Akoya Biosciences pay dividends?

No, Akoya Biosciences does not pay dividends

What sector is Akoya Biosciences in?

Akoya Biosciences is in the Healthcare sector

What industry is Akoya Biosciences in?

Akoya Biosciences is in the Medical Instruments & Supplies industry

What country is Akoya Biosciences based in?

Akoya Biosciences is headquartered in United States

When did Akoya Biosciences go public?

Akoya Biosciences's initial public offering (IPO) was on April 16, 2021

Is Akoya Biosciences in the S&P 500?

No, Akoya Biosciences is not included in the S&P 500 index

Is Akoya Biosciences in the NASDAQ 100?

No, Akoya Biosciences is not included in the NASDAQ 100 index

Is Akoya Biosciences in the Dow Jones?

No, Akoya Biosciences is not included in the Dow Jones index

When was Akoya Biosciences's last earnings report?

Akoya Biosciences's most recent earnings report was on Mar 17, 2025

When does Akoya Biosciences report earnings?

The next expected earnings date for Akoya Biosciences is May 13, 2025

Should I buy Akoya Biosciences stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page